SAN DIEGO — Two proposed new multiple myeloma staging systems offer similar prognostic accuracy compared with the standard staging system, but the new systems provide more refined risk classifications ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and ...

Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group The clinical outcome of multiple myeloma (MM) is heterogeneous.

Multiple myeloma is a rare type of blood cancer that starts in your plasma cells. Your plasma cells are a type of white blood cell inside your bone marrow, the soft inner part of your bones. If you ...

Staging, the process of finding out how advanced the cancer is, is very important because the treatment options and the outlook for recovery and survival depend on the stage of the cancer. Knowing all ...

Multiple myeloma is a cancer of plasma cells, the antibody-making white blood cells that live in your bone marrow. When these cells turn abnormal and multiply, they crowd out healthy blood-forming ...

A blood test is a medical procedure where a sample of a person's blood is taken (called a blood draw) and sent to a lab for analysis. Knowing the results of blood tests helps a physician better ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Multiple myeloma – a rare form of blood cancer – is usually found in people 65 and older. While it’s rare in young adults, a small percentage of people 19-40 also have the disease. Only 10% of people ...